抗生素
微生物学
生物膜
抗菌肽
抗菌剂
金黄色葡萄球菌
耐甲氧西林金黄色葡萄球菌
抗生素耐药性
氨苄西林
生物
医学
细菌
遗传学
作者
Swastik Behera,Sana Mumtaz,Madhuri Singh,Kasturi Mukhopadhyay
出处
期刊:ACS Infectious Diseases
[American Chemical Society]
日期:2023-11-27
卷期号:9 (12): 2436-2447
标识
DOI:10.1021/acsinfecdis.3c00298
摘要
The repotentiation of the existing antibiotics by exploiting the combinatorial potential of antimicrobial peptides (AMPs) with them is a promising approach to address the challenges of slow antibiotic development and rising antimicrobial resistance. In the current study, we explored the ability of lead second generation Ana-peptides viz. Ana-9 and Ana-10, derived from Alpha-Melanocyte Stimulating Hormone (α-MSH), to act synergistically with different classes of conventional antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). The peptides exhibited prominent synergy with β-lactam antibiotics, namely, oxacillin, ampicillin, and cephalothin, against planktonic MRSA. Furthermore, the lead combination of Ana-9/Ana-10 with oxacillin provided synergistic activity against clinical MRSA isolates. Though the treatment of MRSA is complicated by biofilms, the lead combinations successfully inhibited biofilm formation and also demonstrated biofilm disruption potential. Encouragingly, the peptides alone and in combination were able to elicit in vivo anti-MRSA activity and reduce the bacterial load in the liver and kidney of immune-compromised mice. Importantly, the presence of Ana-peptides at sub-MIC doses slowed the resistance development against oxacillin in MRSA cells. Thus, this study highlights the synergistic activity of Ana-peptides with oxacillin advocating for the potential of Ana-peptides as an alternative therapeutic and could pave the way for the reintroduction of less potent conventional antibiotics into clinical use against MRSA infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI